Pillstats
Rx only · Solution · Respiratory (Inhalation)

Revefenacin

Brands: Yupelri · Revefenacin

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCR03BB08
RxCUI (US)2102775
US makers1 labelers
Packages2
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$5.03$10.05$15.08$20.11Jan 2026Jun 2026Jul 2026
$17.472
Latest avg · Jul 22, 2026
-0%
Since Jan 1, 2026
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

3.2K6.3K9.5K13K2025 Q12025 Q22025 Q32025 Q42026 Q1
8.8K
Rx · 2026 Q1
814K
Units dispensed
-10%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Viatris Specialty LLCunknown2SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.